Flow cytometry analysis of the T cell populations in these tumors revealed that the triple combination significantly reduced intra-tumoral Foxp3+ Tregs and yielded a 7-fold increase in the Foxp3+:Treg ratio in the cytotoxic CD8+ T cell population, suggesting that TGF-β inhibition combined with cytotoxic nanomedicine could be a promising therapeutic strategy for TNBC microenvironment normalization and improve anti-tumor immunity41. This evidence concerns the gene TGFB1 and neoplasm.